

Tumor Microenvironment in Primary Liver Cancer

Guest Editors:

Dr. Stefania Mantovani

Division of Clinical Immunology
and Infectious Diseases,
Fondazione IRCCS Policlinico
San Matteo, 27100 Pavia, Italy

Dr. Barbara Oliviero

Division of Clinical Immunology
and Infectious Diseases,
Fondazione IRCCS San Matteo,
27100 Pavia, Italy

Deadline for manuscript
submissions:
closed (28 June 2024)

Message from the Guest Editors

Dear Colleagues,

Liver cancers, including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), remain a global health challenge and their incidence is growing worldwide. It is estimated that, by 2025, >1 million individuals will be affected by liver cancer annually.


In HCC, TME consists of a mixture of three major players including normal, fibrotic and neoplastic areas accompanied by distinct distribution patterns of tumorous, stromal and immune cells, which are relevant to the clinical outcome of patients. In-depth analysis of the immune TME disclosed distinct subclasses of patients showing differences in clinical prognosis and response to personalized treatment.

For this Special Issue of *Cancers*, we invite authors to submit contributions that will provide new insights into compositions and functions of the diverse cell types and their metabolomes, secretomes, exosomes, and other soluble factors, responsible for cancer heterogeneity and tumor evolution, in particular findings that could have a promising translational application.

Dr. Stefania Mantovani

Dr. Barbara Oliviero





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)